Xynomic Buys Rights to Boehringer's Phase II Ready mTORC1/2 Inhibitor

 
• By Sten Stovall
  
Handshake
BI 860585 is a potent and selective ATP-competitive mTOR serine/threonine kinase inhibitor. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip